• Peripheral Immune Dysregulation in Adolescent MDD: Multi-Omi

  2026-06-03

  This study integrates bulk and single-cell RNA sequencing to reveal widespread downregulation of immune-related genes in adolescents with major depressive disorder (MDD). The findings highlight distinct immune signatures compared to adults and suggest that current antidepressant treatments do not normalize this peripheral immune dysregulation, underlining the need for immune-targeted interventions.

• Gut-Brain Cholinergic Signaling in B. fragilis–Mediated Seiz

  2026-06-03

  Jia et al. reveal that Bacteroides fragilis suppresses seizures via gut-brain cholinergic signaling, specifically through the activation of colonic ChAT+ cells and enhanced vagal transmission. These findings bridge microbiota neuroscience and translational epilepsy therapy, offering a mechanistic foundation for microbiota-based interventions in refractory pediatric epilepsy.

• Dabigatran Etexilate: Advancing Oral Anticoagulation for VTE

  2026-06-02

  The reference study evaluates dabigatran etexilate, the first oral direct thrombin inhibitor, detailing its pharmacology, clinical efficacy, and therapeutic positioning versus established anticoagulants for venous thromboembolism (VTE) and atrial fibrillation. The findings highlight dabigatran's predictable anticoagulant profile, reduced need for monitoring, and practical advantages over vitamin K antagonists, with implications for improving VTE prophylaxis in clinical practice.

• GPNMB-Based Model Predicts Immunotherapy Response in ESCC

  2026-06-02

  The reference study introduces a multimodal model that combines circulating GPNMB levels, tumor microenvironment features, and clinical-pathological data to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). This work clarifies the mechanism by which soluble GPNMB induces CD8+ T cell exhaustion, offering a more precise approach for patient stratification and therapy optimization.

• HotStart Universal 2X Green qPCR: Precision in Neurogenetics

  2026-06-01

  Discover how HotStart Universal 2X Green qPCR Master Mix advances real-time PCR gene expression analysis, with a special focus on neurogenetic research and practical insights from recent NEXMIF studies. Explore best practices, assay optimization, and expert recommendations for robust results.

• AT13387 and the Next Era of Hsp90 Inhibition in Cancer Biolo

  2026-06-01

  This thought-leadership article explores AT13387, a next-generation Hsp90 inhibitor, through the lens of recent mechanistic discoveries in regulated cell death and translational oncology. It bridges foundational molecular rationale, experimental data, and strategic protocol guidance, culminating in a forward-looking outlook for cancer biology research.

• Cyclodextrin-Mediated Cholesterol Depletion Inhibits TRPV1/T

  2026-05-31

  This study demonstrates that cyclodextrin derivatives can attenuate TRPV1 and TRPA1 activation-induced nociceptive and neurogenic inflammatory responses by depleting membrane cholesterol. The findings suggest an alternative, non-antagonist approach to modulating pain pathways, with implications for the development of novel analgesic strategies targeting lipid microdomains.

• Dabigatran Etexilate: Transforming Oral Anticoagulant Therap

  2026-05-30

  Dabigatran etexilate introduces a new paradigm in oral anticoagulation by providing rapid, predictable thrombin inhibition without reliance on cytochrome P450 metabolism. This innovation overcomes key limitations of traditional agents and has substantial implications for managing venous thromboembolism and stroke risk in patients with atrial fibrillation.

• Haloprogin: Applied Antifungal Workflows and Troubleshooting

  2026-05-29

  Haloprogin’s broad-spectrum profile and potent MICs enable rigorous research into dermatophyte, Candida, and Gram-positive bacterial infections. This article delivers stepwise protocols, troubleshooting insights, and advanced application guidance, making it essential for labs seeking reliable, evidence-backed workflows.

• Safe DNA Gel Stain: Elevating Cloning Integrity and Laborato

  2026-05-29

  Explore how Safe DNA Gel Stain revolutionizes DNA and RNA gel stain workflows by minimizing DNA damage and enhancing cloning efficiency. This article dives deep into the mechanistic, environmental, and experimental advantages of modern nucleic acid staining, with insights you won't find elsewhere.

• (-)-Blebbistatin: Advanced Protocols for Myosin II Inhibitio

  2026-05-28

  (-)-Blebbistatin stands out as a non-muscle myosin II inhibitor, enabling precision control of actin-myosin interactions in cellular and cardiac assays. This article delivers actionable workflows, troubleshooting insights, and practical parameter guidance to help researchers harness (-)-Blebbistatin for cutting-edge studies in cytoskeletal dynamics and cardiac physiology.

• Substance P in Applied Research: Protocols, Troubleshooting,

  2026-05-28

  Leverage the unique properties of Substance P, a canonical tachykinin neuropeptide, for rigorous pain transmission and neuroinflammation research. This guide details advanced workflows, protocol enhancements, and troubleshooting strategies—anchored by APExBIO’s high-purity Substance P and recent advances in spectral interference management.

• HyperFluor™ 594 Goat Anti-Rabbit IgG: Precision Tools for IS

  2026-05-27

  Explore how the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody enables advanced, multiplexed detection of rabbit antibodies in immunocytochemistry and immunohistochemistry. This article uniquely connects cutting-edge atherosclerosis research with practical protocol optimizations for fluorescence-based assays.

• Tubastatin A Attenuates Cardiac Injury via Pyroptosis and Ne

  2026-05-27

  A recent porcine model study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly reduces myocardial damage following cardiac arrest by inhibiting both pyroptosis and necroptosis. These findings provide mechanistic insight with translational potential for targeting programmed cell death in post-resuscitation cardiac injury.

• Everolimus (RAD001) Protocols: Optimizing mTOR Inhibition in

  2026-05-26

  Everolimus (RAD001) offers cancer researchers a robust, bioavailable tool for dissecting mTOR-driven cell proliferation and viability. This guide translates bench workflows, protocol tunings, and troubleshooting strategies into actionable insights—backed by recent innovations in in vitro drug response evaluation.

16749 records 1/1117 page Next 12345 下5页 Last page